▶ 調査レポート

水痘ワクチンの世界市場:成長・動向・市場規模予測(2020-2025)

• 英文タイトル:Varicella Vaccine Market - Growth, Trends, and Forecast (2020 - 2025)

Mordor Intelligenceが調査・発行した産業分析レポートです。水痘ワクチンの世界市場:成長・動向・市場規模予測(2020-2025) / Varicella Vaccine Market - Growth, Trends, and Forecast (2020 - 2025) / D0-MOR-AP1192資料のイメージです。• レポートコード:D0-MOR-AP1192
• 出版社/出版日:Mordor Intelligence / 2020年4月20日
• レポート形態:英文、PDF、105ページ
• 納品方法:Eメール(受注後2-3営業日)
• 産業分類:健康管理
• 販売価格(消費税別)
  Single User¥446,250 (USD4,250)▷ お問い合わせ
  Team User¥498,750 (USD4,750)▷ お問い合わせ
  Corporate License¥787,500 (USD7,500)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
本調査レポートは、水痘ワクチンの世界市場について調査・分析した資料で、水痘ワクチンの市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。

The Varicella Vaccine Market is expected to register a CAGR of 5.6% during the forecast period. Varicella vaccines contain an attenuated (weakened) live strain of the varicella-zoster (chickenpox) virus. These vaccines stimulate the immune system against the varicella-zoster virus as the infection can cause serious diseases such as herpes zoster and chickenpox. Varicella vaccines are of two types namely monovalent and combination varicella vaccines. The monovalent vaccines contain a single weakened strain of the varicella-zoster virus, however, the combination of varicella vaccines contain multiple strains of infectious agents. These vaccines are used for chickenpox, herpes zoster and mumps, measles, rubella, and varicella immunization. Absence of chickenpox immunization can lead to complications such as bacterial infections of the skin, soft tissues, bones, joints or bloodstream (sepsis), pneumonia, encephalitis, and even death.
As per the study report published in Human Vaccines & Immunotherapeutic 2019, globally annual varicella disease burden is estimated to be 140 million cases, of these 4.2 million cases have severe complications that can lead to hospitalization and death, neonates and the immunocompromised individuals particularly are at high risk.

In addition, according to the Centers for Disease Control and Prevention (CDC), each year in United States approximately 11,000 individuals get hospitalize due to chicken pox complications.

Furthermore, growing awareness regarding varicella vaccines usage, active participation of government in immunization programs and surge in the acceptance of varicella vaccines are the key driving factors in varicella vaccine market.

Key Market Trends

Monovalent Varicella Vaccine Segment is Expected to Hold a Significant Market Share in the Varicella Vaccine Market

Monovalent Varicella Vaccine segment holds a significant market share in varicella vaccine market and is anticipated to show a similar trend over the forecast period as these vaccines exhibit lesser chances of inducing febrile seizures in children compared to combination vaccines. The monovalent vaccines contain a single strain of a single varicella live vaccines, contain a weakened strain of the varicella-zoster virus. These vaccines are used for chickenpox immunization and herpes zoster immunization. According to the Centers for Disease Control and Prevention (CDC), an estimated one million cases of shingles (Herpes Zoster) occur annually in the United States. In addition, approximately 1 out of 3 people in the United States will develop shingles (Herpes Zoster) during their lifetime. Furthermore, easy availability and high adoption of monovalent products are the key driving factors in the monovalent varicella vaccine segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global varicella vaccine market due to the presence of major players involved in the commercialization and development of vaccines in this region. According to the Centers for Disease Control and Prevention (CDC) estimates, more than 3.5 million cases of varicella, 9,000 hospitalizations, and around 100 deaths are prevented by varicella vaccination each year in the United States. Furthermore, the presence of well-established healthcare infrastructure and increasing healthcare spending is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Varicella Vaccine Market is Consolidated competitive and consists of a few major players. Some of the prominent players operating in the varicella vaccine market are GlaxoSmithKline Plc, Merck & Co., Inc, GC Pharma (Green Cross Holdings), Bio-Med Pvt Limited, Novo Medi Sciences Pvt Ltd, Sanofi, Takeda Pharmaceutical Company Limited and Mitsubishi Tanabe Pharma Corporation.

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format
– 3 months of analyst support

レポート目次

1 INTRODUCTION
1.1 Study Assumptions
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Growing Awareness Regarding Use of Varicella Vaccine
4.2.2 Increase in Immunization Programs Across the Globe
4.3 Market Restraints
4.3.1 High Cost of the Vaccine
4.3.2 Time-consuming Process for the Development of Varicella Vaccine
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION
5.1 By Vaccine
5.1.1 Monovalent Varicella Vaccine
5.1.2 Combination Varicella Vaccine
5.2 By Application
5.2.1 Chickenpox Immunization
5.2.2 Herpes Zoster Immunization
5.2.3 Mumps, Measles, Rubella and Varicella Immunization
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East and Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East and Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GlaxoSmithKline Plc
6.1.2 Merck & Co., Inc
6.1.3 GC Pharma (Green Cross Holdings)
6.1.4 Bio-Med Pvt. Limited
6.1.5 Novo Medi Sciences Pvt. Ltd
6.1.6 Sanofi
6.1.7 Takeda Pharmaceutical Company Limited
6.1.8 Mitsubishi Tanabe Pharma Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS